Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients - Kröger, N; Zabelina, T; Klyuchnikov, E (Bone Marrow Transplant, 2013)
et al.